iSBTc 24th Annual Meeting

Annual Meeting Main Page   |   Final Program   |  Program Purpose   |   Faculty   |    Presentation Slides & Schedule  |   Hot Topic Symposium   |   Friend of the President   |  Abstracts   |   Young Investigators   |   Award Winners   |   Photos

October 29 - 31, 2009                                                                        
Gaylord National Hotel and Convention Center
Washington, D.C.

Program Schedule & Slides                                                                                Download Final Program

 To view slides from a presenter, click on the  icon next to their name.
 

Wednesday, October 28
7:45 am - 7:00 pm	iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer For more information on the Workshop, click here.
Thursday, October 29
7:50 am - 8:00 am	President's Welcome Bernard A. Fox, PhD - Earle A. Chiles Research Institute
8:00 am - 8:45 am	Richard V. Smalley, MD Memorial Lectureship The Biology and Therapy of Brain Metastasis  Isaiah J. Fidler, DVM, PhD - MD Anderson Cancer Center
8:45 am - 11:30 am	Plenary Session:  Human Immunology Co-Chairs:     Jacques Banchereau, PhD - Baylor Institute for Immunology Research                       Adrian Hayday, PhD - King's College London
8:45 am - 9:15 am	Dendritic Cells as Therapeutic Vaccines in Cancer Jacques Banchereau, PhD - Baylor Institute for Immunology Research
9:15 am - 9:30 am	Identification of Colon Cancer Associated Antigens which would be Key Therapeutic Targets in the Prevention of Disease Relapse or Progression  Elizabeth K. Broussard, MD - University of Washington Tumor Vaccine Group
9:30 am - 10:00 am	Harnessing Invariant NKT Cells to Abolish the Suppressive Activity of Myeloid Derived Suppressor Cells and Restore Melanoma Specific Immune Response Vincenzo Cerundolo, MD, PhD - University of Oxford - Inst. of Molec. Medicine
10:00 am - 10:15 am	Identification of a Novel CD8+CD57+ T Cell Subset in Human Melanoma Exhibiting an Incompletely Differentiated CTL Phenotype  Richard Wu, BS - MD Anderson Cancer Center
10:45 am - 11:00 am	A Data Analysis Method for Identifying Autoantibody Biomarkers in Cancer Patients Following Immunotherapy  Janet Siebert, MD - CytoAnalytics
11:00 am - 11:30 am	γ8 T Cells-Agents of Tissue and Tumour Immune Surveillance  Adrian Hayday, PhD - King's College London
11:30 am - 1:00 pm	Lunch with Poster Viewing and Exhibits
1:00 pm - 3:00 pm	Plenary Session:  Enhancing Cancer Vaccines / Combinations Co-Chairs:     Jeffrey Schlom, PhD - National Cancer Institute, NIH                       Laurence Zitvogel, MD, PhD - Institute Gustave Roussy
1:00 pm - 1:25 pm	Enhancing Cancer Vaccines as Monotherapy and in Combination Therapies  Jeffrey Schlom, PhD - National Cancer Institute, NIH
1:25 pm - 1:50 pm	Defining the Role of TKIs in Reducing Immune Suppression While Improving T Cell Responsiveness and Efficacy of Immunotherapy for the Treatment of Tumors  James H. Finke, PhD - Cleveland Clinic Foundation
1:50 pm - 2:05 pm	Type-1 Dendritic Cell Vaccines in Combination With Poly-ICLC - Association Between Positive Tetramer Response and 6-Month Progression-Free Survival  Hideho Okada, MD, PhD - University of Pittsburgh Cancer Institute
2:05 pm - 2:30pm	IDO/IDO2 Inhibition: A New Strategy to Drive Immunotherapeutic Responses in Cancer by Reversing Tumoral Immune Tolerance George C. Prendergast, PhD - Lankenau Institute for Medical Research
2:30 pm - 3:00 pm	How to Exploit the Immunogenicity of Chemotherapy or Radiotherapy Towards a Personalized Therapy of Cancer Laurence Zitvogel, MD, PhD - Institute Gustave Roussy
3:00 pm - 3:15 pm	Break
3:15 pm - 4:45 pm	Concurrent Session I:  Regulatory & Activated T Cell Subsets Co-Chairs:     Charles G. Drake, MD, PhD - Johns Hopkins University                       Giorgio Trinchieri, MD - National Cancer Institute
3:15 pm - 3:30 pm	CD81- A New Functional Marker for Tumor-induced Regulatory T Cells that Suppress Priming of Tumor-specific Effector T Cells in Reconstituted, Lymphopenic Hosts Christian H. Poehlein, MD - Earle A. Chiles Research Institute
3:30 pm - 3:55 pm	Regulation of Tumor Immunity by NKT Cell Subsets Masaki Terabe, PhD - National Cancer Institute
3:55 pm - 4:20 pm	IL-17 Secreting CD8 T Cells - Functional Plasticity and Potential Role in Tumor Immunity  Charles G. Drake, MD, PhD - Johns Hopkins University
4:20 pm - 4:45 pm	Interleukin-1 Role in Human TH17 Responses, Dendritic Cell Activation, and Epithelial Cell Transformation  Giorgio Trinchieri, MD - National Cancer Institute
3:15 pm - 4:45 pm	Concurrent Session II:  Monoclonal Antibodies / Combinations Co-Chairs:     Glenn Dranoff, MD - Dana-Farber Cancer Instiute                       Robert L. Ferris, MD, PhD - University of Pittsburgh Cancer Institute
3:15 pm - 3:35 pm	FcγR Mediated Regulation of Adaptive Immunity: Implications for Antibody Therapies  Madhav Dhodapkar, MD - Yale University
3:35 pm - 3:50 pm	Synergy of Radiation and Immune Therapy in Tumor Eradication  Maria Grazia Ruocco, PhD - NYU - School of Medicine, Skirball Institute
3:50 pm - 4:10 pm	Enhancing Cancer Vaccines Glenn Dranoff, MD - Dana-Farber Cancer Institute
4:10 pm - 4:25 pm	Antitumor Activity of Cytotoxic T-Lymphocyte Antigen-4 Blockade Alone or Combined with Paclitaxel, Etoposide, or Gemcitabine in Murine Models Maria Jure-Kunkel, PhD - Bristol-Myers Squibb Company
4:25 pm - 4:45 pm	Immune Activation by Cetuximab Involves NK Cells, CTL and DC Against EGFR in Head and Neck Cancer Robert L. Ferris, MD, PhD, FACS - University of Pittsburgh Cancer Institute
5:00 pm - 5:30 pm	iSBTc Membership Business Meeting
5:30 pm - 7:00 pm	Reception with Poster Viewing
Friday, October 30
8:00 am - 8:45 am	Keynote Address T Cell Recognition and the Coming Golden Age of Human Immunology and Immunotherapy Mark M. Davis, PhD - Howard Hughes Medical Institute / Stanford University School of Medicine
8:45 am - 11:30 am	Plenary Session:  Viral and Cellular Proteomic Targets Co-Chairs:     Lieping Chen, MD, PhD - Johns Hopkins University School of Medicine                       Douglas R. Lowy, MD - National Cancer Institute, CCR
8:45 am - 9:15 am	Current and Future Preventive HPV Vaccines  Douglas R. Lowy, MD - National Cancer Institute, CCR
9:15 am - 9:45 am	Therapeutic Strategies for Human Papillomavirus-Associated Cancers  Karl Münger, PhD - Brigham & Women's Hospital, Harvard Medical School
9:45 am - 10:15 am	Targets of Protective Tumor Immunity Glenn Dranoff, MD - Dana-Farber Cancer Institute
11:00 am - 11:15 am	Definition of the Immunological Properties of Cancer Stem Cells Isolated from Human Glioblastoma  Cristina Maccalli, PhD - San Raffaele Foundation Scientific Institute
11:15 am - 11:30 am	Cell-Free EBV DNA is a Specific Biomarker for Tumour Burden in EBV-Associated Lymphomas Kimberley Jones - Queensland Institute of Medical Research
11:30 am - 1:00 pm	Lunch with Poster Viewing and Exhibits
1:00 pm - 2:20 pm	iSBTc Presidential Session Chair:             Bernard A. Fox, PhD - Earle A. Chiles Research Institute
1:00 pm - 1:20 pm	T-Cell Delivery of Interleukin-12 to the Tumor Microenvironment Triggers Potent Endogenous Anti-Tumor Responses  Sid Kerkar, MD - National Cancer Institute, Center for Cancer Research
1:20 pm - 1:40 pm	Transduction of Tumor-Specific T Cells with the Gene Encoding CXCR2 Improves Migration to Tumor and In Vivo AntiTumor Immune Responses Weiyi Peng, MD, PhD - University of Texas MD Anderson Cancer Center
1:40 pm - 2:00 pm	Eradication of Established CD19-Postive Leukemia Using a Single Injection of Chimeric Immunoreceptor Modified Lentiviral Transduced T Cells in a Xenograft Nog Mouse Model  David M. Barrett, MD, PhD - Children's Hospital of Philadelphia
2:00 pm - 2:20 pm	Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation  Presented by Thomas F. Gajeski, MD, PhD on behalf of Justin P. Kline, MD- University of Chicago
2:20 pm - 2:45 pm	Break
2:45 pm - 4:15 pm	Concurrent Session I:  Manipulation of the Tumor Microenvironment Co-Chairs:     James P. Allison, PhD - Memorial Sloan-Kettering Cancer Center                       Dmitry I. Gabrilovich, MD, PhD - H. Lee Moffitt Cancer Center and Research Institute
2:45 pm - 3:15 pm	Checkpoint Blockade in Tumor Immunotherapy: New Insights and Opportunities  James P. Allison, PhD - Memorial Sloan-Kettering Cancer Center
3:15 pm - 3:30 pm	Manipulation of the Tumor Microenvironment by CTLA-4 Blockade  Padmanee Sharma, MD, PhD - MD Anderson Cancer Center
3:30 pm - 4:00 pm	Myeloid-Derived Suppressor Cells and Tumor Microenvironment Dmitry I. Gabrilovich, MD, PhD - H. Lee Moffitt Cancer Center and Research Institute
4:00 pm - 4:15 pm	Eosinophilic Granulocytes Modulate Tumor Microenvironment by Oxidizing Damage Associated Molecular Pattern Molecules Derived from Necrotic Tumor Cells  Ramin Lotfi, MD - University of Ulm, Institute for Transfusion Medicine
2:45 pm - 4:15 pm	Concurrent Session II:  Targeted Therapeutics and Biological Therapy Co-Chairs:     Richard Jove, PhD - City of Hope Cancer Institute                       David H. Munn, MD - Medical College of Georgia
2:45 pm - 3:15 pm	Targeting Jak-Stat Signaling for Cancer Therapy Richard Jove, PhD - City of Hope Cancer Institute
3:15 pm - 3:45 pm	Small-Molecule Inhibitors of the IDO Pathway as Immune Modulators  David H. Munn, MD - Medical College of Georgia
3:45 pm - 4:00 pm	Soluble, High Affinity T Cell Receptors as Cancer Therapeutics  Bent Jakobsen - Immunocore Ltd.
4:00 pm - 4:15 pm	Small Molecule Curcumin Analogs Induce Apoptosis in Human Melanoma Cells via STAT3 Inhibition but do not Alter the Cellular Response to Immunotherapeutic Cytokines  Gregory B. Lesinski, PhD - The Ohio State University
4:30 pm - 5:00 pm	Update:  2008 Workshop on Cancer & Inflammation: Promise for Biological Therapy  Michael T. Lotze, MD - University of Pittsburgh Cancer Institute
5:00 pm - 5:30 pm	Awards Presentation (View award recipients)
5:30 pm - 7:00 pm	Presidential Reception with Poster Viewing
Saturday, October 31
8:00 am - 10:15 am	Plenary Session:  Adoptive Transfer Co-Chairs:      Carl H. June, MD - University of Pennsylvania                        Steven A. Rosenberg, MD, PhD - National Cancer Institute
8:00 am - 8:30 am	Cell Transfer Therapy for Patients with Metastatic Cancer  Steven A. Rosenberg, MD, PhD- National Cancer Institute
8:30 am - 9:00 am	What are the Functional and Phenotypic Qualities of Therapeutically Successful Anti-Tumor Cells?  Nicholas P. Restifo, MD - National Cancer Institute
9:00 am - 9:15 am	Programming Tumor-Reactive Effector Memory CD8+ T Cells In Vitro Obivates the Requirement for In Vivo Vaccination  Christopher A. Klebanoff, MD - National Institutes of Health, Center for Cancer Research
9:15 am - 9:45 am	Engineered T Cells for Cancer Therapy Carl H. June, MD - University of Pennsylvania
9:45 am - 10:15 am	Adoptive Transfer of T Cells Genetically Modified Using the Sleeping Beauty System  Laurence J.N. Cooper, MD - MD Anderson Cancer Center
10:15 am - 10:20 am	Break
10:20 am - 12:00 pm	Hot Topic Symposium: Positive Immunotherapy Clinical Trial Outcomes Co-Chairs:     Thomas F. Gajewski, MD, PhD - University of Chicago                       Drew M. Pardoll, MD, PhD - Johns Hopkins University School of Medicine
10:20 am - 10:25 am	Welcome and Introductions Thomas F. Gajewski, MD, PhD - University of Chicago
10:25 am - 10:45 am	Therapeutic Vaccines for Lymphoma: A Tale of Bench to Beside Translation Larry W. Kwak, MD, PhD - MD Anderson Cancer Center
10:45 am - 11:05 am	A Phase III Multi-Institutional Randomized Study of Immunization with the gp 100:209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients with Metastatic Melanoma  Doug J. Schwartzentruber, MD, FACS - Goshen Center for Cancer Care
11:05 am - 11:25 am	Development History of Sipuleucel-T: Progress of an Active Immunotherapy for Prostate Cancer  David L. Urdal, PhD - Dendreon Corporation
11:25 am - 11:35 am	NY-ESO-1 Specific Responses in Patients with Advanced Prostate Cancer Treated wtih Ipilimumab  Jianda Yuan, MD, PhD - Memorial Sloan-Kettering Cancer Center
11:35 am - 11:45 am	Circulating Regulatory T Cell Function and Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Poxviral-based Vaccine  Matteo Vergati, MD - National Cancer Institute, Center for Cancer Research
11:45 am - 12:00 pm	Audience Discussion Moderator:    Drew M. Pardoll, MD, PhD - Johns Hopkins School of Medicine